Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL

PHASE1CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

October 18, 2017

Primary Completion Date

August 15, 2022

Study Completion Date

August 15, 2022

Conditions
Multiple MyelomaNon-Hodgkin LymphomaDiffuse Large B Cell LymphomaMantle-Cell LymphomaFollicular LymphomaIndolent B Cell LymphomaPrimary Mediastinal LymphomaLymphoplasmacytic Lymphoma
Interventions
BIOLOGICAL

Nicotinamide Expanded Haploidentical or Mismatched Related Donor Natural Killer Cells

"* Cyclophosphamide 40 mg/kg x 1 day on Day -5~* Fludarabine 25 mg/m\^2 x 3 days (Day -5, Day -4, day-3)"

Trial Locations (1)

55455

Masonic Cancer Center, University of Minnesota, Minneapolis

All Listed Sponsors
lead

Masonic Cancer Center, University of Minnesota

OTHER

NCT03019666 - Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL | Biotech Hunter | Biotech Hunter